SEC Comment Letter 0000000000-26-002905 to Cue Biopharma, Inc. (CUE)
Cue Biopharma, Inc.
Date: March 23, 2026 · CIK: 0001645460 · Accession: 0000000000-26-002905
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-294366
Letter
Re: Cue Biopharma, Inc. Registration Statement on Form S-3 Filed March 16, 2026 File No. 333-294366 Dear Lucinda Warren:
March 23, 2026
Lucinda Warren Chief Financial and Business Officer Cue Biopharma, Inc. 40 Guest Street Boston, Massachusetts 02135
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Caroline Dotolo, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> March 23, 2026 Lucinda Warren Chief Financial and Business Officer Cue Biopharma, Inc. 40 Guest Street Boston, Massachusetts 02135 Re: Cue Biopharma, Inc. Registration Statement on Form S-3 Filed March 16, 2026 File No. 333-294366 Dear Lucinda Warren: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Caroline Dotolo, Esq. </TEXT> </DOCUMENT>